During a nearly two-decade stint as Alnylam’s founding CEO, John Maraganore took a promising but unproven approach for treating genetic disease and built a new class of medicines and what is now a nearly $21 billion company.
His next goal? Helping the next generation of budding biotech entrepreneurs.
Since stepping down as Alnylam CEO in 2021, Maraganore has spent much of his time passing down his knowledge to up-and-coming biotech CEOs. He shared some of that wisdom on Wednesday at the 2023 STAT Summit, from thoughts on how entrepreneurs can prepare themselves for the rough-and-tumble world of drug development to tips on raising money and dealing with the Food and Drug Administration.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect